
|Articles|March 29, 2023
Discussing the Growing Role of CDMOs with Anil Kane (DCAT 2023)
Author(s)Grant Playter
Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry
Advertisement
As part of ongoing coverage of DCAT, the PharmTech editors touched base with Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. In in our discussion, Anil discussed various topics within the outsourcing market, including:
- The increased interest in technologies like cell and gene therapies and oral biologics
- The continued rise of the "end-to-end" CDMO model and why biopharma partners are seeking it out
- Recent investments made in new spaces by Thermo Fisher Scientific
For more of our coverage on DCAT in 2023, viewers can visit
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5




